Article
Yesterday the Food and Drug Administration's (FDA) "Vaccines and Related Biological Products Advisory Committee" conve
All News
Article
Dr. Jack Cush reviews the news, journal reports, survey results and "Back Talk" questions from Rheums.
Article
Bergman and colleagues have studied a large cohort of US rheumatologists and found that nearly half meet at least one criterion defining "burnout" among physicians.
Article
The FDA has approved Gilead Sciences Inc’s antiviral drug remdesivir for treating patients hospitalized with COVID-19, making it the first and only drug approved for the disease in the United States.
Dr. John Cush
Tweet
PI facts: did you know that JAK inhibitors(UPA, Bari, Tofa) have a warning against use w/ severe liver problems. They have not been studied in pts w/ Hepatitis B or C. UPA Bari & toga can be used in mild liver dz; Tofa only at 5 mg/d w/ moderate liver dz https://t.co/lnXrf12tjA
Dr. John Cush
Tweet
Listent to QD Clinics - A Podcast Weekly Compilation - Lessons from the clinic. Dr. Jack Cush discusses triage Rheumatology; Im Not Stupid; & Swollen but Not Painful
iTunes https://t.co/FHJv01Sb3a
SoundCloud https://t.co/fceBeXGu09
Dr. John Cush
Tweet
RheumNow Podcast is up! Back Talk: Taking Calls ^ Questions from Listeners - watch it here>https://t.co/KuTtu5JawO or listen to the Podcast on iTunes> https://t.co/FHJv01AAbC
OR SoundCloud> https://t.co/ICukowi11u
Dr. John Cush
Tweet
Population study of 11 million, shows incidence of OPTIC NEURITIS is 3.7 /100K Pt-Yrs. Strongest association with multiple sclerosis (MS) and weaker associations with Behçet disease, sarcoidosis, and Sjögren syndrome. https://t.co/LVw0fcq1F1
Dr. John Cush
Tweet
Randomized trial of 491 probable nonhospitalized COVID-19 pts shows that HCQ (given 800 mg, followed by 600 mg in 6 -8 hrs, then 600 mg qd x 4d) or placebo shows no reduction in symptom severity in outpatients with early, mild COVID-19.https://t.co/yVWGRr6jfr
Dr. John Cush
Tweet
How are you consuming Virtual CME Rheumatology conferences
Adam J Brown
Tweet
Working on an Endocarditis for the Rheumatologist podcast. fast facts!!!
1️⃣ 20% no fever
2️⃣ 20% joint pain at presentation
3️⃣ >40% splenomegly
4️⃣ 90% anemia
5️⃣ most common rash = petechiae (Osler node/janeway/Roth spots 10% combined!)
#rheumatology #cleclinicrheum #immunology
Dr. John Cush
Tweet
FDA approved its 1st drug to treat COVID-19 - the antiviral drug Veklury (remdesivir) for for acute care treatment of COVID-19 requiring hospitalization. Approval based on 3 clinical trials showing clinical improvement, but no change in mortality rates. https://t.co/IrA7oKMuGq
Dr. John Cush
Tweet
Study from China finds that hemophagocytic lymphohistiocytosis (HLH) was a rare (4.2%) but fatal (77.8%) complication in myositis patients (DM, PM, or CADM). Risk factors include baseline Dz activity, worsening ILD and infection https://t.co/QDN1DYzl5p
Dr. John Cush
Tweet
How are you consuming Virtual CME Rheumatology conferences
Dr. John Cush
Tweet
Study from NY shows that Death rates from COVID-19 have dropped (in hospitalized pts) from a high of 27% down to 3%. Partly because a younger, healthier are now getting infected, arriving @ hospital w/ less-severe Sxs. Also improved COVID medical care https://t.co/8aFuVHUDjY
Dr. John Cush
Tweet
#LTF
Listen
to
Fauci
Dr. John Cush
Tweet
Korea National Health databased looked at Fracture rates in RA patients taking TNFis, abatacept, or tocilizumab betw 2002 to 2016. They found no difference in Fx risk related to the biologic taken. https://t.co/W2dWWseXTc
Dr. John Cush
Tweet
QD Clinic - Triage Rheumatology - Lessons from the clinic. Dr. Jack Cush discusses What constitutes urgent, emergent and Patients you should see https://t.co/0mKvbB9Knv https://t.co/YYN7nOum9t
Dr. John Cush
Tweet
QD Video - I'm Not Stupid (IgG4) - Lessons from the clinic. Dr. Jack Cush discusses an IgG4 case and the power of discussion https://t.co/RDIVEeyqxW
The Lancet Rheumatology
Tweet
NEW RESEARCH: Abatacept in the treatment of diffuse cutaneous #SystemicSclerosis; clinically meaningful improvements in mRSS and other outcome measures were observed when patients transitioned to open-label #abatacept treatment https://t.co/tDSo3u8hAY #LancetRheumatology https://t.co/Nc8XYc1URW
